ERBB2 and breast cancer: In this study, tissue-derived spheroids from HER2 negative patients were studied to determine differences in the observed treatment efficacy for the most frequently applied treatment schemes in the primary, recurrent, and metastatic setting and compared to results obtained from spheroids generated from HER2 negative breast cancer cell lines.